Table 3.
Patient code |
Age at diagnosis |
Sex | ASE* value |
APC mutation/variant |
|||
---|---|---|---|---|---|---|---|
Exon | Variant | SNP code | Effect (if known) | ||||
CASE 1 | 64 | F | 0.81 | 16 | c.4479G>A | rs41115 | p.Thr1493Thr |
CASE 2 | 61 | F | 1.58 | 14 | c.1635A>G | rs351771 | p.Ala545Ala |
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 3 | 56 | M | 0.75 | wt | / | ||
CASE 7 | 55 | M | 1.59 | 14 | c.1635A>G | rs351771 | p.Ala545Ala |
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
CASE 12 | 68 | F | 0.93 | IVS6 | c.645+32C>T | rs29009961 | / |
14 | c.1635A>G | rs351771 | p.Ala545Ala | ||||
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 16 | 56 | M | 1.57 | IVS1 | c.1-111T>C† | - | / |
16 | c.3949G>C | rs1801166 | p.Glu1317Gln | ||||
16 | c.4479A | rs 41115 | p.1493Thr | ||||
CASE 18 | 76 | F | 1.78 | wt | / | ||
CASE 19 | 43 | F | 0.43 | 7 | c.646C>T | p.Arg216X | |
CASE 22 | 66 | F | 1.64 | 16 | c.4479G>A | rs41115 | p.Thr1493Thr |
CASE 23 | 65 | M | 2.46 | 16 | c.4479A | rs41115 | p.1493Thr |
CASE 25 | 66 | M | 1.72 | IVS1 | c.1-111T>C† | - | / |
16 | c.3949G>C | rs1801166 | p.Glu1317Gln | ||||
16 | c.4479A | rs41115 | p.1493Thr | ||||
CASE 28 | 76 | M | 1.76 | wt | / | ||
CASE 29 | 68 | M | 0.98 | 14 | c.1635A>G | rs351771 | p.Ala545Ala |
16 | c.3512G>A | p.Arg1171His | |||||
CASE 31 | 60 | M | 0.68 | IVS6 | c.645+32C>T | rs29009961 | / |
14 | c.1635A>G | rs351771 | p.Ala545Ala | ||||
CASE 32 | 48 | F | 0.95 | 16 | c.5268G>T | rs866006 | p.Ser1756Ser |
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 33 | 45 | F | 0.94 | wt | / | ||
CASE 34 | 74 | M | 1.70 | 16 | c.4479G>A | rs41115 | p.Thr1493Thr |
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 37 | 71 | M | 1.78 | wt | / | ||
CASE 44 | 69 | F | 1.55 | 14 | c.1635A>G | rs351771 | p.Ala545Ala |
16 | c.4479G>A | rs41115 | p.Thr1493Thr | ||||
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 49 | 77 | F | 1.59 | IVS3 | c.220+4G>A† | - | / |
16 | c.4479G>A | rs41115 | p.Thr1493Thr | ||||
16 | c.5034A>G | - | p.Gly1678Gly | ||||
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
CASE 50 | 41 | M | 1.58 | 16 | c.5268G>T | rs866006 | p.Ser1756Ser |
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
CASE 51 | 51 | M | 0.94 | 14 | c.1635A>G | rs351771 | p.Ala545Ala |
16 | c.5268G>T | rs866006 | p.Ser1756Ser | ||||
16 | c.5465A>T | rs459552 | p.Asp1822Val | ||||
16 | c.7862C>G | rs72541816 | p.Ser2621Cys | ||||
CASE 53 | 36 | M | 0.96 | 16 | c.4479A | rs41115 | p.1493Thr |
ASE values outside 1.645 SD are in bold
Predicted effects on splicing and transcriptional regulation of these novel APC variants were evaluated in silico using fruitfly software (www.fruitfly.org) and a transcriptional regulatory element database (www.rulai.cshl.edu), respectively.